GLP-1 receptor agonists driving growing demand for nonsurgical treatments to address “Ozempic face”
FRIDAY, Feb. 7, 2025 (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of a survey released by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS).
The 2024 AAFPRS annual online survey was sent in December 2024 to academy members.
Rhinoplasties, facelifts (including partial facelifts), and blepharoplasties remained the top three surgical procedures in 2024. However, facial plastic surgeons reported a 50 percent rise in the average number of fat grafting procedures performed over the past year, a trend likely fueled by patients addressing “Ozempic face” and aiming to restore lost volume while enhancing facial contours. One in four surgeons anticipate that GLP-1 RA medications will drive a growing demand for nonsurgical treatments, such as injectable fillers and skin tightening procedures, as patients seek less invasive options to manage aesthetic changes resulting from weight loss. Additionally, 10 percent of AAFPRS members started personally prescribing GLP-1 RA medications. Other noted trends included the desire for facial rejuvenation as part of “menopause makeovers.”
Fifty-seven percent of respondents predicted that regenerative medicine, including treatments such as platelet-rich plasma and exosome-based therapies, will become a major area of innovation in the aesthetic field. In addition, men are increasingly seeking cosmetic procedures, with 92 percent of survey respondents reporting male patients in their practice; blepharoplasty, rhinoplasty, and facelifts were the most requested procedures.
“Just like their female counterparts, neurotoxins, fillers, and skin treatments remain the top three nonsurgical procedures among men,” Patrick Byrne, M.D., president of the AAFPRS, said in a statement. “This trend highlights the growing acceptance of aesthetic treatments among men and their changing approach to self-care.”
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease 
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer 
Type 2 Diabetes Linked to Worse Menopausal Symptoms 
Premature Menopause Linked to Increased Risk for Hypertension 
Onset of Mortality, Morbidity Delayed for Offspring of Centenarians 
Antenatal Complications Increased With Maternal Multiple Long-Term Conditions 
Phthalates From Personal Care Products Tied to Higher BP in Pregnancy 
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
